Antiangiogenic treatment in patients with hepatocellular carcinoma

Abstract

Hepatocellular carcinoma (HCC) is usually diagnosed in advanced stage and numerous of patients present poor clinical condition which is a reason for small fraction of patients treated with surgery. Among operated patients, high percentage presents inoperable recurrence of the cancer. Introduction of effective systemic treatment is necessary in this group of patients. Antiangiogenetic agents are the first active class of medications used in advanced HCC. These drugs are recently tested in adjuvant setting after successful surgery in less advanced cases of HCC. Combinations of antiangiogenetic agents and other drugs of molecular targeted therapies are searched.